Revance Therapeutics Inc. (Nasdaq: RVNC) reported positive 6-month results from a Phase 2 study of injectable RT002 sending the stock price soaring $10.86 to close at $37.59.
Revance reports upbeat study results
October 29, 2015 at 20:11 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.